1. Isoliquiritigenin Containing PH Sensitive Micelles for Enhanced Anti-Colitis Activity.
- Author
-
Shi F, Du M, Wang Q, Adu-Frimpong M, Li C, Zhang X, Ji H, Toreniyazov E, Cao X, Wang Q, and Xu X
- Subjects
- Rats, Animals, Drug Delivery Systems methods, Anti-Inflammatory Agents pharmacology, Hydrogen-Ion Concentration, Drug Carriers chemistry, Micelles, Colitis, Chalcones
- Abstract
Isoliquiritigenin (ISL) is known to have a variety of pharmacological activities, but its poor water solubility limits its application. In order to improve the bioavailability of ISL and its anti-colitis activity, this study aims to develop an effective drug delivery system loaded with ISL. In this study, ISL pH-sensitive micelles (ISL-M) were prepared by thin film hydration method. The micellar size (PS), polydispersity index (PDI), electrokinetic potential (ζ-potential), drug loading (DL), encapsulation rate (EE) and other physical parameters were characterized. The storage stability of ISL-M was tested, release in vitro and pharmacokinetic studies in rats were performed, and the anti-inflammatory effect of ISL-M on ulcerative colitis induced by dextran sulfate sodium (DSS) was evaluated. The results showed that PS, PDI, ZP, EE% and DL% of ISL-M were 151.15±1.04 nm, 0.092±0.014, -31.32±0.721 mV, 93.97±1.53 % and 8.42±0.34 %, respectively. Compared with unformulated ISL (F-ISL), the cumulative release rate of ISL-M in the three different media was significantly increased and showed a certain pH sensitivity. The area under drug curve (AUC
0-t ) and peak concentration (Cmax ) of ISL-M group were 2.94 and 4.06 times higher than those of ISL group. In addition, ISL-M is expected to develop new methods for increasing the bioavailability and anti-inflammatory activity of ISL., Competing Interests: Declaration of Competing Interest The authors declare no conflict of interest., (Copyright © 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF